|
Clinical implication of mass-spectrometry-based selected reaction monitoring (SRM) assay in non-small cell lung cancer (NSCLC) patients exhibiting ALK gene rearrangement. |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
Patents, Royalties, Other Intellectual Property - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Leadership - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
|
|
Employment - OncoPlex Diagnostics |
Leadership - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
Patents, Royalties, Other Intellectual Property - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |